Morte por falência múltipla de órgãos em paciente com COVID-19 grave, AIDS, comprometimento cardiovascular e infecções pulmonares prévias
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Jun 12, 2024
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Relatar um caso de coinfecção pelo SARS-CoV-2/HIV em um paciente com histórico recente de infecções pulmonares, que teve parada cardiopulmonar no dia de sua internação para tratar da COVID-19, falecendo alguns dias depois de falência múltipla de órgãos. Detalhamento de caso: Um homem de 33 anos, imunossuprimido (em abandono de tratamento para o HIV) deu entrada no serviço de pronto-atendimento com sintomas respiratórios e testou positivo para SARS-CoV-2. Durante a internação, o paciente teve parada cardiopulmonar e apresentou intenso perfil inflamatório, infecção fúngica, sepse, acidose metabólica, hipertensão arterial, trombose, hemorragia, além de lesão hepática, muscular e renal. Por fim, o paciente evoluiu para falência de múltiplos órgãos, indo à óbito. Considerações finais: A grave imunodeficiência causada pelo HIV, associada a doenças cardiopulmonares de base, contribui para desfechos letais da COVID-19.
##plugins.themes.bootstrap3.article.details##
Como Citar
Medros JuniorF., SouzaP. O. de, PaulaJ. E. F. B. de, GonzalezM. F. da S. R., SilvaC. G. da, Barreto-VieiraD. F., & BandeiraD. M. (2024). Morte por falência múltipla de órgãos em paciente com COVID-19 grave, AIDS, comprometimento cardiovascular e infecções pulmonares prévias. Revista Eletrônica Acervo Saúde, 24(6), e15610. https://doi.org/10.25248/reas.e15610.2024
Seção
Estudos de Caso
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. ALSHARIF N, et al. Two pandemics intertwined around one patient: Interstitial pneumonia as the first presentation of HIV/AIDS, be it Pneumocystis jirovecii, cytomegalovirus, SARS-CoV2 or all? A case report. Heliyon, 2023; 9(9): e19615.
2. BASSO RP, et al. COVID-19-Associated Histoplasmosis in an AIDS Patient. Mycopathologia, 2021; 186(1): 109-112.
3. BANSAL N, et al. SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward. Transfusion Clinique et Biologique, 2022; 29(2): 161.
4. BERTOLINI M, et al. COVID-19 associated with AIDS-related disseminated histoplasmosis: a case report. Int J STD AIDS, 2020; 31(12): 1222-1224.
5. BO XU, et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. Journal of Infection, 2020; 81(1): e51-60.
6. BUDHIRAJA R, et al. Endothelial dysfunction in pulmonary hypertension. Circulat, 2004; 109(2): 159-65.
7. CDC. Centers for Disease Control and Prevention. COVID-19 and HIV. 2023. Disponível em: https://www.cdc.gov/hiv/basics/covid-19.html. Acessed in: 25 november 2023.
8. DANDACHI D, et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clinical Infectious Diseases, 2021; 73(7): e1964-72.
9. DAODU J, et al. A rare case of AIDS co-infected with COVID-19 presenting with disseminated Herpes zoster complicated with CMV and Varicella zoster virus meningoencephalitis. Acta Biomed., 2022; 93(6): e2022326.
10. DÍEZ C, et al. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. HIV Med., 2021; 22(9): 867-876.
11. DE FIGUEIREDO IR, et al. Pneumocystosis pneumonia: a comparison study between HIV and non-HIV immunocompromised patients. Pulmonology, 2019; 25(5): 271-4.
12. EJAMO JY, et al. COVID-19 vaccine acceptance among people living with HIV: A systematic review and meta-analysis. Trop Med Int Health, 2023; 28(8): 601-611.
13. HELMS J, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive care medicine, 2020; 46(6): 1089-98.
14. KADIRVELU B, et al. Variation in global COVID-19 symptoms by geography and by chronic disease: A global survey using the COVID-19 Symptom Mapper. EClinicalMedicine, 2022; 45: 101317.
15. KANWUGU ON e ADADI P. HIV/SARS‐CoV‐2 coinfection: a global perspective. Journal of medical virology, 2021; 93(2): 726-32.
16. KARMEN-TUOHY S, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. Journal of acquired immune deficiency syndromes, 1999.
17. HARIYANTO TI e ROSALIND J. Human immunodeficiency virus and mortality from coronavirus disease 2019: A systematic review and meta-analysis, 2021; 22: 1220.
18. HAPID MH and DEWI TS. COVID-19 Infection as an Exacerbated Factor of Oral Candidiasis in HIV/AIDS Patient. Int Med Case Rep J., 2023; 16: 303-310.
19. HOFFMANN M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020; 181(2): 271-80.
20. LEITE RO, et al. ATPergic signaling disruption in human sepsis as a potential source of biomarkers for clinical use. Clin Exp Med., 2023; 10.1007/s10238-023-01045-w.
21. MAARTENS G e BOULLE A. CD4 T-cell responses to combination antiretroviral therapy. The Lancet, 2007; 370(9585): 366-8.
22. MELLOR MM, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS, 2021; 35: F1-f10.
23. MIR T, et al. Coronavirus disease 2019 (COVID-19): Multisystem review of pathophysiology. Annals of Medicine and Surgery, 2021; 69: 102745.
24. NAVEED M, et al. Review of potential risk groups for coronavirus disease 2019 (COVID-19). New Microbes and New Infections, 2021; 41: 100849.
25. PIPITÒ L, et al. Hemophagocytic lymphohistiocytosis secondary to histoplasmosis: A case report in a patient with AIDS and recent SARS-CoV-2 infection and minireview. Heliyon, 2023; 9(8): e18537.
26. PHILIP T, et al. Spontaneous pneumothorax and COVID-19: Precipitants to a complex HIV-AIDS diagnosis. Radiol Case Rep., 2023; 18(3): 1197-1200.
27. PENG X, et al. Sharing CD4+ T cell loss: when COVID-19 and HIV collide on immune system. Frontiers in immunology, 2020; 11: 3307.
28. PLUMMER MM and PAVIA CS. COVID-19 Vaccines for HIV-Infected Patients. Viruses, 2021; 13(10): 1890.
29. RAVETTI CG, et al. Estudo de pacientes reanimados pós-parada cardiorrespiratória intra e extra-hospitalar submetidos à hipotermia terapêutica. Revista Brasileira de Terapia Intensiva, 2009; 21: 369-375.
30. TIEMTORE-KAMBOU BM, et al. Aspects scanographiques de la pneumopathie ā COVID-19 ā Ouagadougou: Étude multicentrique ā propos de 1017 cas. Journal of Medical Imaging and Radiation Sciences, 2022; 53(4): 704-13.
31. YANG J, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis., 2020; 94: 91-95.
32. WORLD HEALTH ORGANIZATION. 2023 World Health Organization Coronavirus (COVID-19) Dashboard. Disponível em: https://covid19.who.int/. Access in: 3 september 2023.
33. WORLD HEALTH ORGANIZATION. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection, 15 July 2021. World Health Organization; 2021.
2. BASSO RP, et al. COVID-19-Associated Histoplasmosis in an AIDS Patient. Mycopathologia, 2021; 186(1): 109-112.
3. BANSAL N, et al. SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward. Transfusion Clinique et Biologique, 2022; 29(2): 161.
4. BERTOLINI M, et al. COVID-19 associated with AIDS-related disseminated histoplasmosis: a case report. Int J STD AIDS, 2020; 31(12): 1222-1224.
5. BO XU, et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. Journal of Infection, 2020; 81(1): e51-60.
6. BUDHIRAJA R, et al. Endothelial dysfunction in pulmonary hypertension. Circulat, 2004; 109(2): 159-65.
7. CDC. Centers for Disease Control and Prevention. COVID-19 and HIV. 2023. Disponível em: https://www.cdc.gov/hiv/basics/covid-19.html. Acessed in: 25 november 2023.
8. DANDACHI D, et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clinical Infectious Diseases, 2021; 73(7): e1964-72.
9. DAODU J, et al. A rare case of AIDS co-infected with COVID-19 presenting with disseminated Herpes zoster complicated with CMV and Varicella zoster virus meningoencephalitis. Acta Biomed., 2022; 93(6): e2022326.
10. DÍEZ C, et al. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. HIV Med., 2021; 22(9): 867-876.
11. DE FIGUEIREDO IR, et al. Pneumocystosis pneumonia: a comparison study between HIV and non-HIV immunocompromised patients. Pulmonology, 2019; 25(5): 271-4.
12. EJAMO JY, et al. COVID-19 vaccine acceptance among people living with HIV: A systematic review and meta-analysis. Trop Med Int Health, 2023; 28(8): 601-611.
13. HELMS J, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive care medicine, 2020; 46(6): 1089-98.
14. KADIRVELU B, et al. Variation in global COVID-19 symptoms by geography and by chronic disease: A global survey using the COVID-19 Symptom Mapper. EClinicalMedicine, 2022; 45: 101317.
15. KANWUGU ON e ADADI P. HIV/SARS‐CoV‐2 coinfection: a global perspective. Journal of medical virology, 2021; 93(2): 726-32.
16. KARMEN-TUOHY S, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. Journal of acquired immune deficiency syndromes, 1999.
17. HARIYANTO TI e ROSALIND J. Human immunodeficiency virus and mortality from coronavirus disease 2019: A systematic review and meta-analysis, 2021; 22: 1220.
18. HAPID MH and DEWI TS. COVID-19 Infection as an Exacerbated Factor of Oral Candidiasis in HIV/AIDS Patient. Int Med Case Rep J., 2023; 16: 303-310.
19. HOFFMANN M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020; 181(2): 271-80.
20. LEITE RO, et al. ATPergic signaling disruption in human sepsis as a potential source of biomarkers for clinical use. Clin Exp Med., 2023; 10.1007/s10238-023-01045-w.
21. MAARTENS G e BOULLE A. CD4 T-cell responses to combination antiretroviral therapy. The Lancet, 2007; 370(9585): 366-8.
22. MELLOR MM, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS, 2021; 35: F1-f10.
23. MIR T, et al. Coronavirus disease 2019 (COVID-19): Multisystem review of pathophysiology. Annals of Medicine and Surgery, 2021; 69: 102745.
24. NAVEED M, et al. Review of potential risk groups for coronavirus disease 2019 (COVID-19). New Microbes and New Infections, 2021; 41: 100849.
25. PIPITÒ L, et al. Hemophagocytic lymphohistiocytosis secondary to histoplasmosis: A case report in a patient with AIDS and recent SARS-CoV-2 infection and minireview. Heliyon, 2023; 9(8): e18537.
26. PHILIP T, et al. Spontaneous pneumothorax and COVID-19: Precipitants to a complex HIV-AIDS diagnosis. Radiol Case Rep., 2023; 18(3): 1197-1200.
27. PENG X, et al. Sharing CD4+ T cell loss: when COVID-19 and HIV collide on immune system. Frontiers in immunology, 2020; 11: 3307.
28. PLUMMER MM and PAVIA CS. COVID-19 Vaccines for HIV-Infected Patients. Viruses, 2021; 13(10): 1890.
29. RAVETTI CG, et al. Estudo de pacientes reanimados pós-parada cardiorrespiratória intra e extra-hospitalar submetidos à hipotermia terapêutica. Revista Brasileira de Terapia Intensiva, 2009; 21: 369-375.
30. TIEMTORE-KAMBOU BM, et al. Aspects scanographiques de la pneumopathie ā COVID-19 ā Ouagadougou: Étude multicentrique ā propos de 1017 cas. Journal of Medical Imaging and Radiation Sciences, 2022; 53(4): 704-13.
31. YANG J, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis., 2020; 94: 91-95.
32. WORLD HEALTH ORGANIZATION. 2023 World Health Organization Coronavirus (COVID-19) Dashboard. Disponível em: https://covid19.who.int/. Access in: 3 september 2023.
33. WORLD HEALTH ORGANIZATION. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection, 15 July 2021. World Health Organization; 2021.